Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10626142 Purification platform for bispecific antibodies

Patent 10626142 was granted and assigned to Regeneron Pharmaceuticals on April, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

Current Assignee

Regeneron Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10626142

Date of Patent

April 21, 2020

Patent Application Number

14808171

Date Filed

July 24, 2015

Patent Citations Received

‌

US Patent 12103960 VEGF traps and mini-traps and methods for treating ocular disorders and cancer

‌

US Patent 11459374 Anti-VEGF protein compositions and methods for producing the same

‌

US Patent 11472861 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

‌

US Patent 11485770 Anti-VEGF protein compositions and methods for producing the same

‌

US Patent 11505594 Anti-VEGF protein compositions and methods for producing the same

‌

US Patent 11505593 Anti-VEGF protein compositions and methods for producing the same

‌

US Patent 12077570 Anti-VEGF protein compositions and methods for producing the same

...

Patent Primary Examiner

‌

Daniel E Kolker

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10626142 Purification platform for bispecific antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API